Posaconazole oral suspension 40 mg/mL

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fungal Infections

Conditions

Fungal Infections

Trial Timeline

Feb 1, 2012 โ†’ Nov 1, 2013

About Posaconazole oral suspension 40 mg/mL

Posaconazole oral suspension 40 mg/mL is a pre-clinical stage product being developed by Merck for Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01436578. Target conditions include Fungal Infections.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01436578Pre-clinicalCompleted

Competing Products

20 competing products in Fungal Infections

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
41
MicafunginAstellas PharmaPhase 1
33
MicafunginAstellas PharmaPre-clinical
23
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
85
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPre-clinical
23
FluconazoleAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPhase 1
33
Micafungin + PlaceboAstellas PharmaPhase 3
77
Posaconazole + Voriconazole + PlaceboMerckPhase 3
77
caspofungin acetate + Comparator: Micafungin sodiumMerckPhase 3
77
caspofungin acetateMerckPhase 3
77
PosaconazoleMerckPhase 1
33
PosaconazoleMerckApproved
85
Posaconazole IV 6 mg/kg + Posaconazole PFS 6 mg/kgMerckPhase 2
52
Posaconazole 12 mg/kg/day BID + Posaconazole 18 mg/kg/day BID + Posaconazole 18 mg/kg/day TID + Posaconazole 12 mg/kg/day TIDMerckPhase 1
33
caspofungin acetateMerckPhase 2
52
PosaconazoleMerckPhase 1
33